Results 151 to 160 of about 72,405 (280)

Bone marrow sarcoidosis in Takayasu arteritis: Case report and literature review. [PDF]

open access: yesMedicine (Baltimore)
Fakih O   +5 more
europepmc   +1 more source

Treatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Systematic review of 108 studies with a total of 182 patients with interstitial granulomatous dermatitis (IGD). IGD was frequently associated with systemic conditions or drug exposure. Management includes careful medication review and prompt withdrawal of potential triggers. Corticosteroids (systemic and topical) were commonly effective, while biologic
Francesco Bellinato   +4 more
wiley   +1 more source

Use of Two Biologics During Pregnancy: Infliximab and Vedolizumab: A Case Study. [PDF]

open access: yesTher Drug Monit
Hoekstra B   +6 more
europepmc   +1 more source

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis

open access: yes, 2015
Ofir Elalouf, Ori Elkayam Department of Rheumatology, Sackler Faculty of Medicine, Tel Aviv Medical Center, Tel Aviv, Israel Abstract: The introduction of TNFα blockers has revolutionized the treatment of ankylosing spondylitis (AS).
Elalouf O, Elkayam O
core  

Immune checkpoint inhibitor‐induced colitis or infectious mimic? Considering Paeniclostridium sordellii

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Thomas Breakell   +8 more
wiley   +1 more source

Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
No evidence of an increased risk of incident cancer or KC was observed with biologic versus non‐biologic systemic therapies or across the biologic classes evaluated. Abstract Background There are concerns that biologic therapies for psoriasis may increase cancer risk. Objectives To compare risks of (i) incident cancer excluding keratinocyte carcinomas (
Oras A. Alabas   +9 more
wiley   +1 more source

Efficacy and Safety of Risankizumab Among Patients With Ulcerative Colitis in East Asia: A Post Hoc Analysis of Two Randomized Clinical Trials

open access: yesJournal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim Risankizumab, a monoclonal interleukin 23p19 antibody, is a treatment for ulcerative colitis. This post hoc analysis reports the efficacy and safety of risankizumab for ulcerative colitis in patients in East Asia from the global phase 3 clinical trials. Methods In the 12‐week, phase 2b/3 induction study (NCT03398148), adults
Ken Takeuchi   +14 more
wiley   +1 more source

Successful bimekizumab retreatment after secondary failure in multi‐biologic‐resistant psoriasis

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nicole Kah Mun Yoong   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy